|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 23 |
| 2 | Overview on Submodule Topologies,Modeling,Modulation,Control Schemes,Fault Diagnosis,and Tolerant Control Strategies of Modular Multilevel Converters显示文摘In the present scenario,modular multilevel converters(MMCs)are considered to be one of the most promising and effective topologies in the family of high-power converters because of their modular design and good scalability;MMCs are extensively used in high-voltage and high-power applications.Based on their unique advantages,MMCs have attracted increasing attention from academic circles over the past years.Several studies have focused on different aspects of MMCs,including submodule topologies,modeling schemes,modulation strategies,control schemes for voltage balancing and circulating currents,fault diagnoses,and fault-tolerant control strategies.To summarize the current research status of MMCs,all the aforementioned research issues with representative research approaches,results and characteristics are systematically overviewed.In the final section,the current research status of MMCs and their future trends are emphasized. | Fujin Deng Yongqing Lu Chengkai Liu Qian Heng Qiang Yu Jifeng Zhao | 2020 | Chinese Journal of Electrical Engineering2020，6，1： | 15 |
| 3 | Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer:an open-label,randomized controlled phase 3 trial(ORIENT-3)显示文摘Background:Treatment options for Chinese patients with locally advanced or metastatic squamous-cell non-small-cell lung cancer(sqNSCLC)after failure of first-line chemotherapy are limited.This study(ORIENT-3)aimed to evaluate the efficacy and safety of sintilimab versus docetaxel as second-line treatment in patients with locally advanced or metastatic sqNSCLC.Methods:ORIENT-3 was an open-label,multicenter,randomized controlled phase 3 trial that recruited patients with stage IIIB/IIIC/IV sqNSCLC after failure with first-line platinum-based chemotherapy.Patients were randomized in a 1:1 ratio to receive either 200 mg of sintilimab or 75 mg/m^(2) of docetaxel intravenously every 3 weeks,stratified by the Eastern Cooperative Oncology Group performance status.The primary endpoint was overall survival(OS)in the full analysis set(FAS).Secondary endpoints included progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),duration of response(DoR)and safety.Results:Between August 25,2017,and November 7,2018,290 patients were randomized.For FAS,10 patients fromthe docetaxel armwere excluded.Themedian OS was 11.79(n=145;95%confidence interval[CI],10.28-15.57)months with sintilimab versus 8.25(n=135;95%CI,6.47-9.82)months with docetaxel(hazard ratio[HR]:0.74;95%CI,0.56-0.96;P=0.025).Sintilimab treatment significantly prolonged PFS(median 4.30 vs.2.79 months;HR:0.52;95%CI,0.39-0.68;P<0.001)and showed higher ORR(25.50%vs.2.20%,P<0.001)and DCR(65.50%vs.37.80%,P<0.001)than the docetaxel arm.The median DoRwas 12.45(95%CI,4.86-25.33)months in the sintilimab arm and 4.14(95%CI,1.41-7.23)months in the docetaxel arm(P=0.045).Treatment-related adverse events of grade≥3were reported in 26(18.1%)patients in the sintilimab arm and 47(36.2%)patients in the docetaxel arm.Exploratory biomarker analysis showed potential predictive values of expression levels of two transcription factors,including OVOL2(HR:0.35;P<0.001)and CTCF(HR:3.50;P<0.001),for sintilimab treatment.Conclusions:Compared with docetaxel,sintilimab significantly improved the OS,PFS,and ORR of Chinese patients with previously treated locally advanced or metastatic sqNSCLC. | Yuankai Shi Lin Wu Xinmin Yu Puyuan Xing Yan Wang Jianying Zhou Airong Wang Jianhua Shi Yi Hu Ziping Wang Guangyu An Yong Fang Sanyuan Sun Caicun Zhou Changli Wang Feng Ye Xingya Li Junye Wang Mengzhao Wang Yunpeng Liu Yanqiu Zhao Ying Yuan Jifeng Feng Zhendong Chen Jindong Shi Tao Sun Gang Wu Yongqian Shu Qisen Guo Yi Zhang Yong Song Shucai Zhang Yuan Chen Wei Li Hongrui Niu Wenwei Hu Lijun Wang Jianan Huang Yang Zhang Ying Cheng Zhengdong Wu Bo Peng Jiya Sun Christoph Mancao Yanqi Wang Luyao Sun | 2022 | Cancer Communications2022，42，12： | 8 |
| 4 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer(ESWN 01):a prospective randomized,multicenter,open-labeled phase 3 trial显示文摘Background:The benefit of systemic treatments in esophageal squamous cell carcinoma(ESCC)which has pro-gressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established.We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monotherapy in recurrent or metastatic ESCC patients who had resistance to platinum-or taxane-based chemotherapy.Methods:We conducted a prospective randomized,multicenter,open-label,phase 3 trial in 15 centers across China.Eligible patients were adults with histologically confirmed recurrent or metastatic ESCC,and were randomly assigned(ratio,1:1)to receive either irinotecan plus S-1(intravenous infusion of irinotecan[160 mg/m2]on day 1 and oral S-1[80-120 mg]on days 1-10,repeated every 14 days)or oral S-1 monotherapy(80-120 mg/day on days 1-14,repeated every 21 days)using a central computerized minimization procedure.The primary endpoint was progression-free survival(PFS).Results:Between December 23,2014 and July 25,2016,we screened 148 patients and randomly assigned 123 patients to receive either irinotecan plus S-1 regimen(n=61)or S-1 monotherapy(n=62).After a median follow-up of 29.2 months(95%confidence interval[CI]17.5-40.9 months),the median PFS was significantly longer in the irinotecan plus S-1 group than in the S-1 monotherapy group(3.8 months[95%CI 2.9-4.3 months]vs.1.7 months[95%CI 1.4-2.7 months],hazard ratio=0.58,95%CI 0.38-0.86,P=0.006).The objective response rates were 24.6%in the irinotecan plus S-1 group and 9.7%in the S-1 monotherapy group(P=0.002).The patients in the irinotecan plus S-1 group presented with increased rates of grade 3-4 leukopenia(16.4%vs.0%),neutropenia(14.8%vs.1.6%),and nausea(4.9%vs.0%).No significant difference in grade 3-4 diarrhea and no treatment-related deaths were observed in both groups.Conclusions: The combination of irinotecan with S-1 was similarly tolerable but significantly prolonged PFS compared to S-1 monotherapy as a second- or third-line treatment in patients with recurrent or metastatic ESCC. | Jing Huang Binghe Xu Ying Liu Junxing Huang Ping Lu Yi Ba Lin Wu Yuxian Bai Shu Zhang Jifeng Feng Ying Cheng Jie Li Lu Wen Xianglin Yuan Changwu Ma Chunhong Hu Qingxia Fan Xi Wang | 2019 | Cancer Communications2019，39，1： | 8 |
| 5 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 7 |
| 6 | Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01(a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma显示文摘Objective: This study aimed to compare the pharmacokinetic, pharmacodynamic and safety profiles of HLX01(a rituximab biosimilar) and reference rituximab sourced from China(Mab Thera?;rituximab-CN).Methods: Here we report the results of two phase 1 studies. In the phase 1 a, open-label, dose-escalation study(NCT03218072, CTR20140400), eligible patients received 250, 375 and 500 mg/m^(2) HLX01 sequentially at 7-day intervals, after confirming no dose-limiting toxicity(DLT). In the phase 1 b, double-blind study(NCT02584920,CTR20140764), eligible patients were given a single dose of 375 mg/m^(2) HLX01 or rituximab-CN. The primary endpoints included safety and tolerability parameters for the phase 1 a and the area under the plasma concentrationtime curve from time zero to day 91(AUC0-91 d) for the phase 1 b study. Equivalence was concluded if 90%confidence interval(90% CI) for the geometric least squares mean ratio(GLSMR) fell in the pre-specified equivalence criteria(80%-125%).Results: Between June 20, 2014 and January 5, 2015, 12 patients were enrolled in the phase 1 a study. The pharmacokinetics of HLX01 showed dose proportionality and accumulation to steady state. HLX01 was well tolerated, with no serious adverse events(AEs), discontinuations or DLTs. Between November 8, 2014 and August13, 2015, 87 eligible patients were enrolled in the phase 1 b study, including 43 who received HLX01 and 44 who were treated with rituximab-CN. The equivalence endpoint was met with GLSMR for AUC0-91 d being 89.6%(90% CI: 80.4%-99.8%). AEs, anti-drug antibodies, and CD19+ and CD20+ B lymphocyte counts were similar between the HLX01 and rituximab-CN treatment groups.Conclusions: Treatment with HLX01 was safe and well tolerated in Chinese patients with B-cell lymphoma.HLX01 and rituximab-CN have similar pharmacokinetic, pharmacodynamic and safety profiles. | Yuankai Shi Qingyuan Zhang Xiaohong Han Yan Qin Xiaoyan Ke Hang Su Li Liu Jinxiang Fu Jie Jin Jifeng Feng Xiaonan Hong Xiaohong Zhang Depei Wu Bin Jiang Xiaodong Dong | 2021 | Chinese Journal of Cancer Research2021，33，3： | 5 |
| 7 | Structural evolution and superconductivity tuned by valence electron concentration in the Nb-Mo-Re-Ru-Rh high-entropy alloys显示文摘The crystal structure and physical properties of Nb_(25)Mo_(5+x)Re_(35)Ru_(25-x)Rh_(10)(0≤x≤10)and Nb_(5)Mo_(35-y)Re_(15+y)Ru_(35)Rh_(10)(0≤y≤15)high-entropy alloys(HEAs)have been studied by X-ray diffraction,electrical resistivity,magnetic susceptibility,and specific heat measurements.The results show that the former HEAs with valence electron concentration(VEC)values of 6.7-6.9 crystallize in a noncentrosymmetric cubicα-Mn structure,while the latter ones with VEC values of 7.1-7.25 adopt a centrosymmetric hexagonal close-packed(hcp)structure.Despite different structures,both series of HEAs are found to be bulk superconductors with a full energy gap,and the superconducting transition temperature Tc tends to decrease with the increase of VEC.Nevertheless,the Tc values of the hcp-type HEAs are higher than those of theα-Mn-type ones,likely due to a stronger electron phonon coupling.Furthermore,we show that VEC and electronegativity difference are two key parameters to control the stability ofα-Mn and hcp-type HEAs.These results not only are helpful for the design of such HEAs,but also represent the first realization of structurally different HEA superconductors without changing the constituent elements. | Bin Liu Jifeng Wu Yanwei Cui Qjnqing Zhu Guorui Xiao Siqi Wu Guang-han Cao Zhi Ren | 2021 | Journal of Materials Science & Technology2021，，26： | 5 |
| 8 | A strategy for service realization in service-oriented design显示文摘Recently service orientation is becoming a mainstream approach for building large scale software systems. A key requirement in service-oriented design is the de- pendability of service. It stipulates that the behavior of services is controllable. Formal models can aid in constructing software in a dependable manner. They can describe ser- vices precisely and compose them together consistently. This paper presents a strategy for service realization based on a novel layered formal model. When a service is provided or required via internet, the semantic consistency becomes critical issue. Our architecture tackles the issue by proposing a novel scheme: defining contract of a service to keep semantic information. Although service-oriented design is our prime target, the contract models, to a large extent, are independent of the framework of design and therefore ap- plicable to large scale software design in general. | LIU Jing HE Jifeng LIU Zhiming | 2006 | Science in China(Series F)2006，49，6： | 4 |
| 9 | Regulating catalyst morphology to boost the stability of Ni–Mo/Al_(2)O_(3) catalyst for ebullated-bed residue hydrotreating显示文摘Hydrotreating of vacuum residue by ebullated-bed shows tremendous significance due to more stringent environmental regulations and growing demand for lighter fuels. However, enhancing the catalyst stability still remains as a challenging task. Herein, two Ni–Mo/Al_(2)O_(3) catalysts with distinct morphologies(i.e., spherical and cylindrical) were first designed, and the morphology effect on deactivation was systematically elucidated employing multi-characterizations, such as HRTEM with EDX mapping, electron microprobe analysis, FT-IR, TGA and Raman. It is found that spherical catalyst exhibits superior hydrotreating stability over 1600 h. The carbonaceous deposits on spherical catalyst with less graphite structure are lighter, and the coke weight is also smaller. In addition, the metal deposits uniformly distribute in the spherical catalyst, which is better than the concentrated distribution near the pore mouth for the cylindrical catalyst. Furthermore, the intrinsic reason for the differences was analyzed by the bed expansion experiment. Higher bed expansion rate together with the better mass transfer ability leads to the enhanced performance. This work sheds new light on the design of more efficient industrial hydrotreating catalyst based on morphology effect. | Huihong Zhu Zhiwei Mao Bin Liu Tao Yang Xiang Feng Hao Jin Chong Peng Chaohe Yang Jifeng Wang Xiangchen Fang | 2021 | Green Energy & Environment2021，6，2： | 4 |
| 10 | Design, Synthesis and Insecticidal Activity of Novel Anthranilic Diamides Containing Oxime Ester and Diacylhydrazine Moieties显示文摘 | LIU Chen ZHANG Jifeng ZHOU Yunyun WANG Baolei XIONG Lixia LI Zhengming | 2014 | Chemical Research in Chinese Universities2014，30，2： | 4 |
| 11 | Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening显示文摘 | Hui Wang Lei Wang Zheng Wu Rong Sun Haifeng Jin Jifeng Ma Lili Liu Rui Ling Jun Yi Ling Wang Jiefang Bian Jianghao Chen Nanlin Li Shifang Yuan Jun Yun | 2014 | Medical Oncology2014，，12： | 4 |
| 12 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 3 |
| 13 | PINK1 kinase dysfunction triggers neurodegeneration in the primate brain without impacting mitochondrial homeostasis显示文摘In vitro studies have established the prevalent theory that the mitochondrial kinase PINK1 protects neurodegeneration by removing damaged mitochondria in Parkinson's disease(PD).However,difficulty in detecting endogenous PINK1 protein in rodent brains and cell lines has prevented the rigorous investigation of the in vivo role of PINK1.Here we report that PINK1 kinase form is selectively expressed in the human and monkey brains.CRISPR/Cas9-mediated deficiency of PINK1 causes similar neurodegeneration in the brains of fetal and adult monkeys as well as cultured monkey neurons without affecting mitochondrial protein expression and morphology.Importantly,PINK1 mutations in the primate brain and human cells reduce protein phosphorylation that is important for neuronal function and survival.Our findings suggest that PINK1 kinase activity rather than its mitochondrial function is essential for the neuronal survival in the primate brains and that its kinase dysfunction could be involved in the pathogenesis of PD. | Weili Yang Xiangyu Guo Zhuchi Tu Xiusheng Chen Rui Han Yanting Liu Sen Yan Qi Wang Zhifu Wang Xianxian Zhao Yunpeng Zhang Xin Xiong Huiming Yang Peng Yin Huida Wan Xingxing Chen Jifeng Guo Xiao-Xin Yan Lujian Liao Shihua Li Xiao-Jiang Li | 2022 | Protein & Cell2022，13，1： | 3 |
| 14 | Emerging technologies in Si active photonics显示文摘Silicon photonics for synergistic electronic–photonic integration has achieved remarkable progress in the past two decades. Active photonic devices, including lasers, modulators, and photodetectors, are the key challenges for Si photonics to meet the requirement of high bandwidth and low power consumption in photonic datalinks. Here we review recent efforts and progress in high-performance active photonic devices on Si, focusing on emerging technologies beyond conventional foundry-ready Si photonics devices. For emerging laser sources,we will discuss recent progress towards efficient monolithic Ge lasers, mid-infrared GeSn lasers, and high-performance In As quantum dot lasers on Si for data center applications in the near future. We will then review novel modulator materials and devices beyond the free carrier plasma dispersion effect in Si, including GeSi and graphene electro-absorption modulators and plasmonic-organic electro-optical modulators, to achieve ultralow power and high speed modulation. Finally, we discuss emerging photodetectors beyond epitaxial Ge p–i–n photodiodes, including GeSn mid-infrared photodetectors, all-Si plasmonic Schottky infrared photodetectors, and Si quanta image sensors for non-avalanche, low noise single photon detection and photon counting. These emerging technologies, though still under development, could make a significant impact on the future of large-scale electronic Silicon photonics for synergistic electronic-photonic integration has achieved remarkable progress in the past two decades. Active photonic devices, including lasers, modulators, and photodetectors, are the key challenges for Si photonics to meet the requirement of high bandwidth and low power consumption in photonic datalinks. Here we review recent efforts and progress in high-performance active photonic devices on Si, focusing on emerging technologies beyond conventional foundry-ready Si photonics devices. For emerging laser sources, we will discuss recent progress towards efficient monolithic Ge lasers, mid-infrared GeSn lasers, and high-performance In As quantum dot lasers on Si for data center applications in the near future. We will then review novel modulator materials and devices beyond the free carrier plasma dispersion effect in Si, including GeSi and graphene electro-absorption modulators and plasmonic-organic electro–optical modulators, to achieve ultralow power and high speed modulation. Finally, we discuss emerging photodetectors beyond epitaxial Ge p–i–n photodiodes, including GeSn mid-infrared photodetectors, all-Si plasmonic Schottky infrared photodetectors, and Si quanta image sensors for non-avalanche, low noise single photon detection and photon counting. These emerging technologies, though still under development, could make a significant impact on the future of large-scale electronic–photonic integration with performance inaccessible from conventional Si photonics technologies-photonic integration with performance inaccessible from conventional Si photonics technologies. | Xiaoxin Wang Jifeng Liu | 2018 | Journal of Semiconductors2018，39，6： | 3 |
| 15 | Changes in Soil Enzyme Activity and Nutrient Content in Different Years of Continuous Cropping Tobacco Fields显示文摘In order to find out changes in the main fertility indicators of continuous cropping tobacco fields in Henan Province with years of continuous cropping,5 typical tobacco fields( Jia County,Shaoling District,Fangcheng County,Xiangcheng County,and Song County) were studied. Indicators in question included activity of main enzymes( sucrase,urease,catalase,and acid phosphatase),p H value,organic matters,total nitrogen,available phosphorus and available potassium. The results indicate that in most tobacco fields,the activity of sucrase and urease increased in two years of continuous cropping,later,it showed a declining trend with increase in years of continuous cropping; in some fields,it directly declined with increase in years of continuous cropping; the activity of catalase increased in two years of continuous cropping,later,it showed a declining trend with increase in years of continuous cropping,and it became stable after three years of continuous cropping;generally,the activity of acid phosphatase declined with increase in the years of continuous cropping within 3 years continuous cropping,later,it became stable. Except Fangcheng County,the soil p H value of other districts( counties) generally declined with increase in years of continuous cropping,and it was in the range of 5. 6-6. 8. With the increase in continuous cropping,the soil organic matters( SOM) in tobacco fields of Jia County and Song County declined,changes of SOM in tobacco fields of Fangcheng County and Xiangcheng County were not obvious,and SOM showed the trend of first decline then rise in Shaoling District. In most tobacco fields( Jia County,Xiangcheng County,and Song County),the total nitrogen showed a declining trend; in Shaoling District,it showed a trend of first decline then rise; in Fangcheng County,it showed a rising trend. The available phosphorus firstly slightly declined then rose in tobacco fields of Shaoling District and Song County; it showed a trend of first rise then decline in Jia County; there were no obvious changes in Fangcheng County and Xiangcheng County. Changes in the available potassium were different in tobacco fields. In sum,there are certain rules for changes in soil enzyme activity and nutrient content in tobacco fields in Henan Province,but changes are not completely the same. It is concluded that the site conditions and farming activities exert a certain influence on soil enzyme activity,p H value,organic matters,and nitrogen,phosphorus and potassium content. Therefore,to solve obstacles in continuous cropping of tobacco fields,different regions should take different measures. | Jifeng CHEN Hui SUN Yang XIA Kaixuan CAI Hongyuan LIU Yuanyuan LI Ruiliang GUO Bei HOU Shuai FENG Xiaoxin JIANG | 2017 | Asian Agricultural Research2017，9，5： | 2 |
| 16 | Current management of chemotherapy-induced neutropenia in adults:key points and new challenges显示文摘Chemotherapy-induced neutropenia(CIN)is a potentially fatal and common complication in myelosuppressive chemotherapy.The timing and grade of CIN may play prognostic and predictive roles in cancer therapy.CIN is associated with older age,poor functional and nutritional status,the presence of significant comorbidities,the type of cancer,previous chemotherapy cycles,the stage of the disease,specific chemotherapy regimens,and combined therapies.There are many key points and new challenges in the management of CIN in adults including:(1)Genetic risk factors to evaluate the patient’s risk for CIN remain unclear.However,these risk factors urgently need to be identified.(2)Febrile neutropenia(FN)remains one of the most common reasons for oncological emergency.No consensus nomogram for FN risk assessment has been established.(3)Different assessment tools[e.g.,Multinational Association for Supportive Care in Cancer(MASCC),the Clinical Index of Stable Febrile Neutropenia(CISNE)score model,and other tools]have been suggested to help stratify the risk of complications in patients with FN.However,current tools have limitations.The CISNE score model is useful to support decision-making,especially for patients with stable FN.(4)There are still some challenges,including the benefits of granulocyte colony stimulating factor treatment and the optimal antibiotic regimen in emergency management of FN.In view of the current reports,our group discusses the key points,new challenges,and management of CIN. | Committee of Neoplastic Supportive-Care(CONS),China Anti-Cancer Association Committee of Clinical Chemotherapy,China Anti-Cancer Association Yi Ba Yuankai Shi Wenqi Jiang Jifeng Feng Ying Cheng Li Xiao Qingyuan Zhang Wensheng Qiu Binghe Xu Ruihua Xu Bo Shen Zhiguo Luo Xiaodong Xie Jianhua Chang Mengzhao Wang Yufu Li Yuerong Shuang Zuoxing Niu Bo Liu Jun Zhang Li Zhang Herui Yao Conghua Xie Huiqiang Huang Wangjun Liao Gongyan Chen Xiaotian Zhang Hanxiang An Yanhong Deng Ping Gong Jianping Xiong Qinghua Yao Xin An Cheng Chen Yanxia Shi Jialei Wang Xiaohua Wang Zhiqiang Wang Puyuan Xing Sheng Yang Chenfei Zhou | 2020 | Cancer Biology & Medicine2020，17，4： | 2 |
| 17 | In Vivo and In Vitro Pharmacological Studies of Methoxycarbonyl-Carboetomidate显示文摘 | Ervin Pejo Joseph F. Cotten Elizabeth W. Kelly Ri Le Ge Gregory D. Cuny Joydev K. Laha Jifeng Liu Xiang Jie Lin Douglas E. Raines | 2012 | Anesthesia & Analgesia2012，，： | 2 |
| 18 | Hybrid MARTE statecharts显示文摘当模特儿和即时、嵌入的系统(MARTE ) 的分析的说明在即时、嵌入的系统的域是统一当模特儿的语言(UML ) 的扩展。尽管 MARTE 时间模型提供支持描述分离、稠密的钟,最大的努力到目前为止被放在分离 MARTE 模型的说明和分析上。探讨混合即时、嵌入的系统,我们建议用 MARTE 和混合自动机的理论扩大 statecharts。我们把这延期混血儿 MARTE 称为 statecharts。它在那在混合自动机上提供改进:逻辑时间变量和测时学的时间变量被统一。混合 MARTE statecharts 的正式句法和语义基于标记的转变系统和实时转变系统被给。作为案例研究,我们与混合 MARTE statecharts 为一个火车控制系统的行为建模表明利益。 | Jing LIU Ziwei LIU Jifeng HE Freederic MALLET Zuohua DING | 2013 | Frontiers of Computer Science2013，7，1： | 2 |
| 19 | EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation显示文摘Objective:To investigate the potential of HS-10182,a second-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI),as a radiosensitizer in non-small cell lung cancer(NSCLC).Methods:Two cell lines of NSCLCs,A549 that possesses wild-type(WT)EGFRs and H1975 that possesses EGFR L858R/T790M double mutations,were treated with HS-10182 at various concentrations,and cell viabilities were determined using the MTS assay.The cells were tested by clonogenic survival assays to identify the radiosensitivity of both groups.Western blot was performed to analyze the expression of phosphorylated EGFR,AKT,DNA-dependent protein kinase,and catalytic subunit(DNA-PKcs)proteins.Immunofluorescence analyses were performed to examine the formation and changes in nuclearγ-H2AX foci.Cell apoptosis was examined by flow cytometry and Western blots for cleaved caspase-3,-8,-9,and cleaved poly ADP-ribose polymerase(PARP).Furthermore,we established xenograft models in mice and the effects of different treatments on tumor growth were then assessed.Results:Clonogenic survival assays revealed that HS-10182 significantly enhanced the radiosensitivity of H1975 cells but not A549cells[dose enhancement ratios(DERs)=2.36(P<0.05)vs.1.43(P>0.05)].Western blot results showed that HS-10182 increased the levels of cleaved caspase-3,-8,-9,and cleaved PARP in H1975 cells but not in A549 cells.In addition,flow cytometry analysis showed that HS-10182 enhanced irradiation-induced apoptosis in H1975.Immunofluorescence results found that HS-10182increased the average number ofγ-H2AX foci after irradiation in H1975 cells,but not in A549 cells.Combined radiation and HS-10182 treatment increased the expression of DNA-PKcs but this increase was more significant in H1975 cells than in A549 cells.Moreover,HS-10182 suppressed the increased expression of Rad50 in H1975 cells in response to irradiation.In vivo experiments found that the combined therapy significantly inhibited tumor growth.Conclusions:HS-10182 enhances the radiosensitivity of H1975 cells which is possibly because that HS-10182 could enhance irradiation-induced apoptosis,increase irradiation-induced DNA damage,and cause a delay in DNA damage repair.Our findings suggest that radiotherapy combined HS-10182 is a novel treatment for lung cancer cells which have acquired the T790M mutation.HS-10182 could be brought to the clinic as a radiosensitizer in NSCLCs with the EGFR T790M mutation. | Yang Chen Youyou Wang Lujun Zhao Ping Wang Jifeng Sun Rudi Bao Chenghai Li Ningbo Liu | 2018 | Cancer Biology & Medicine2018，15，1： | 2 |
| 20 | Active and stable Cu doped NiMgAlO catalysts for upgrading ethanol to n-butanol显示文摘Upgrading ethanol to n-butanol is an attractive way for renewable n-butanol production. Herein, Cu was selected to modify NiMgAlO catalysts for improving ethanol conversion and n-butanol selectivity. Over the optimized 2%Cu-NiMgAlO catalyst, ethanol conversion and n-butanol selectivity were enhanced to 30.0% and 64.2%, respectively, in 200 h time on stream at 523 K. According to physicochemical characterizations and theoretical calculations, the key role of multiple active sites in this reaction was extensively investigated. The plate-like structure of hydrotalcite was maintained over 2%Cu-NiMgAlO catalysts, with an average Ni particle size of ca. 5.4 nm. The presence of Cu species created CuNi alloy sites and Lewis acid-base pairs, and increased hydrogen transfer and condensation reactions, resulting in elevated ethanol conversion and n-butanol selectivity. Additionally, CuNi alloy had a strong interaction with CuNiMgAl oxides, forming homogeneous boundary due to their close ionic radius and lattice matching, and afforded the long time stability in the ethanol to n-butanol reaction. | Zhinuo Wang Ming Yin Jifeng Pang Xianquan Li Yanan Xing Yang Su Shimin Liu Xiaoyan Liu Pengfei Wu Mingyuan Zheng Tao Zhang | 2022 | Journal of Energy Chemistry2022，31，9： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员